PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
Basel – The Basel pharmaceutical company Novartis has acquired Selexys Pharmaceuticals Corporation. The US company is working on an antibody for reducing pain crises in sickle cell disease.
Novartis had obtained the exclusive rights to acquire Selexys back in 2012 and has now exercised those rights after it received the results of a Phase II trial evaluating the use of the antibody SelG1. The results will be presented to the public in early December.
Selexys developed SelG1 to reduce vaso-occlusive pain crises, a major complication of sickle cell disease (SCD), that occur when sickle-shaped blood cells block blood flow through blood vessels.
“Sickle cell disease affects millions of people around the world and there are limited therapies available for treatment of vaso-occlusive pain crises, a very common complication of the disease,” said Bruno Strigini, CEO of Novartis Oncology.
“With this acquisition, Novartis is able to leverage its leadership in hematology research to advance development of a potential new treatment option for patients living with this debilitating condition.”